Seagen To Surge Ahead As ADCs Become Frontline Cancer Therapies
Padcev Plus Keytruda To Become Bladder Cancer Blockbuster
Putting its CEO crisis and takeover rumors behind it, Seagen has big plans to expand its leading position in antibody-drug conjugates in 2023.
You may also be interested in...
Results of the HER2CLIMB-02 study supported Tukysa combinations with antibody-drug conjugates. However, treatment discontinuations drew caution.
Pfizer and Seagen reportedly are in merger discussions, signaling Pfizer’s willingness to invest significantly in antibody-drug conjugates (ADCs) for cancer.
Deal Snapshot: The Dutch biotech planned to move its preclinical candidate, the EGFR-targeting LAVA-1223, into the clinic later this year. Seagen has shown interest in business development as Merck merger talks have quieted down.